Literature DB >> 1053932

Serum ferritin in acute leukaemia at presentation and during remission.

D H Parry, M Worwood, A Jacobs.   

Abstract

In patients with acute myeloblastic leukaemia the mean serum ferritin concentration showed a twenty-five-fold increase compared with normal people, and in children with acute lymphoblastic leukaemia (A.L.L.) there was a thirteen-fold increase. The high concentration of circulating ferritin seemed to be related to increased synthesis by leukaemic cells. The return of serum concentrations to normal in A.L.L. patients after successful chemotherapy suggested that ferritin concentration may be a useful index of active disease and may help in prognosis.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1053932      PMCID: PMC1672022          DOI: 10.1136/bmj.1.5952.245

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  6 in total

1.  Ferritin in normal erythrocytes, lymphocytes, polymorphs, and monocytes.

Authors:  M Summers; M Worwood; A Jacobs
Journal:  Br J Haematol       Date:  1974-09       Impact factor: 6.998

2.  Ferritin synthesis in normal and leukaemic leukocytes.

Authors:  G P White; M Worwood; D H Parry; A Jacobs
Journal:  Nature       Date:  1974-08-16       Impact factor: 49.962

3.  Ferritin in blood cells from normal subjects and patients with leukaemia.

Authors:  M Worwood; M Summers; F Miller; A Jacobs; J A Whittaker
Journal:  Br J Haematol       Date:  1974-09       Impact factor: 6.998

4.  Serum ferritin concentration and iron stores in normal subjects.

Authors:  G O Walters; F M Miller; M Worwood
Journal:  J Clin Pathol       Date:  1973-10       Impact factor: 3.411

5.  Five-year follow-up of "total therapy" of childhood lymphocytic leukemia.

Authors:  D Pinkel
Journal:  JAMA       Date:  1971-04-26       Impact factor: 56.272

6.  Ferritin in serum: diagnosis of iron deficiency and iron overload in infants and children.

Authors:  M A Siimes; J E Addiego; P R Dallman
Journal:  Blood       Date:  1974-04       Impact factor: 22.113

  6 in total
  16 in total

Review 1.  A possible role for secreted ferritin in tissue iron distribution.

Authors:  Esther G Meyron-Holtz; Shirly Moshe-Belizowski; Lyora A Cohen
Journal:  J Neural Transm (Vienna)       Date:  2011-02-06       Impact factor: 3.575

2.  Serum ferritin during unmaintained remission in acute lymphoblastic leukaemia.

Authors:  D H Parry; C Ricketts; A Jacobs
Journal:  Br Med J       Date:  1978-11-11

3.  Evaluation of serum ferritin levels and other hematological parameters in a Nigerian population.

Authors:  O A Oluboyede; E A Usanga; F A Lukanmbi; O A Ajayi
Journal:  J Natl Med Assoc       Date:  1983-09       Impact factor: 1.798

4.  Clinical evaluation of serum ferritin to iron ratio in malignant diseases.

Authors:  R Morita; M Yoshii; K Nakajima; T Kohsaka; M Miki; K Torizuka
Journal:  Eur J Nucl Med       Date:  1981

5.  Letter: alpha2H-globulin and ferritin.

Authors:  A Jacobs; M Wagstaff; M Worwood
Journal:  Br Med J       Date:  1975-09-13

Review 6.  Clinical pharmacokinetics of iron preparations.

Authors:  E Harju
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

7.  Cloning, characterization, expression, and chromosomal localization of a human ferritin heavy-chain gene.

Authors:  M W Hentze; S Keim; P Papadopoulos; S O'Brien; W Modi; J Drysdale; W J Leonard; J B Harford; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

8.  Tissue ferritin concentration and prognosis in carcinoma of the breast.

Authors:  R E Weinstein; B H Bond; B K Silberberg; C B Vaughn; P Subbaiah; D R Pieper
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

Review 9.  Serum ferritin and malignant tumours.

Authors:  A Jacobs
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

10.  Folic acid binding protein in acute myeloid leukaemia.

Authors:  D W Gorst; M Courtis; I W Delamore
Journal:  J Clin Pathol       Date:  1976-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.